Firebrick Pharma Ltd (ASX:FRE)’s Peter Molloy speaks to Proactive about the company’s breakthrough product, the Nasodine® nasal spray. Nasodine is a treatment for the common cold with an iodine base that’s designed to kill viruses in the nose. Firebrick is in the middle of human clinical trials as it seeks approval for the treatment in Australia. Down the line, Nasodine could even have implications for pandemic viral diseases like COVID-19.
Firebrick Pharma targets the common cold with Nasondine® solution
